Contacts EN IT Search form Search for Molmed Home Company Clinical studies Pipeline Technological platforms GMP Solutions Partnering Investors Average Pharmacovigilance Pharmacovigilance To report suspected adverse reactions due to the administration of the drug Zalmoxis , please write to zalmoxis@molmed.com or contact the following telephone numbers: tel . +39 02 212771 mobile +39 335 7225892 fax +39 02 21277239. INFORMATION FOR THE PHARMACOVIGILANCE ACTIVITY INHERENT THE PROCESSING OF PERSONAL DATA Company Business model History Management Scientific Advisory Board Open positions Clinical studies TK NGR-hTNF FAQ Pipeline TK NGR-hTNF CAR-CD44v6 Flat Technological Gene and cell therapy Vascular targeting Patents Publications GMP Solutions Development GMP production Quality check Quality Assurance Regulatory Affairs production sites Track record Partnering Collaborations Investors MolMed on the stock exchange Corporate governance Shareholder information Budgets and reports Presentations Analysts Press releases Investor events Financial Calendar Average Events News MolMed SpA Via Olgettina, 58 - 20132 Milan, Italy | Tel. +39 0221277.1 - Fax +39 02 21277.325 | info@molmed.com - www.molmed.com | Privacy & Cookie Policy Share capital € 21,819,020.83 fully paid-up - REA n.1506630 - Registration number in the Milan Company Reg. - CF and VAT number 11887610159 Home Company Clinical studies Pipeline Technological platforms GMP Solutions Partnering Investors Average Pharmacovigilance